Drawing from previous research findings, it has been reported that certain AML treatment protocols, which combine RA (all-trans retinoic acid) with conventional anthracycline-based frontline chemotherapy, have yielded notable improvements in survival rates, particularly in cases where a mutation in the gene responsible for encoding nucleophosmin 1 (NPM1) is present [21, 22]. Here, NPM1 is linked to acute myeloid leukemia.